Dermapharm Holding SE
Offers dermatological, skin care, and allergy medicines.
Launch date
Employees
Market cap
$1.9b
Enterprise valuation
$3.0b (Public information from Sep 2024)
Share price
€35 DMP.F
Hünenberg Canton of Zug (HQ)
Financials
Estimates*
| EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 794m | 943m | 1.0b | 1.1b | 1.2b | 1.2b | 1.3b |
| % growth | 13 % | 19 % | 9 % | 11 % | 3 % | 5 % | 5 % |
| EBITDA | 191m | 348m | 329m | 261m | 305m | 327m | 347m |
| % EBITDA margin | 24 % | 37 % | 32 % | 23 % | 26 % | 27 % | 27 % |
| Profit | 85.8m | 210m | 134m | 62.4m | 109m | 127m | 138m |
| % profit margin | 11 % | 22 % | 13 % | 5 % | 9 % | 10 % | 11 % |
| EV / revenue | 4.5x | 5.5x | 2.3x | 2.8x | 2.3x | 2.1x | 1.9x |
| EV / EBITDA | 18.6x | 14.9x | 7.3x | 12.3x | 8.8x | 7.9x | 7.2x |
| R&D budget | 12.7m | 14.2m | 13.2m | 10.6m | - | - | - |
| R&D % of revenue | 2 % | 2 % | 1 % | 1 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €328m Valuation: €1.5b 3.2x EV/LTM Revenues 13.3x EV/LTM EBITDA | IPO | |
| Total Funding | - | ||
Related Content
Recent News about Dermapharm Holding SE
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Dermapharm Holding SE
Edit
ACQUISITION by Dermapharm Holding SE Jan 2023
ACQUISITION by Dermapharm Holding SE Dec 2021
